MedTrace Logo

The HER Project: HRD in EGFR-mutated NSCLC

NCT07303218 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-31

No results posted yet for this study

Summary

This observational retrospective-prospective study aims to evaluate the prevalence of homologous recombination deficiency (HRD) in metastatic EGFR mutated NSCLC and to assess its correlation with clinical and molecular features. Based on the hypothesis that HRD identifies a distinct EGFRm subgroup with prognostic value and a potential sensitivity to PARP inhibitor-based strategies, translational analysis will be performed with multiple pre-clinical models, ranging from human cancer cells to murine models.

Conditions

  • EGFR
  • Non Small Cell Lung Cancer
  • Homologous Recombination Deficiency
  • PARP Inhibitor

Interventions

OTHER

No Intervention: Observational Cohort

Observational study only; participants receive standard-of-care treatments not assigned by the study

Sponsors & Collaborators

  • IRCCS San Raffaele

    lead OTHER

Principal Investigators

  • Francesca Rita Ogliari, Medical Doctor · IRCCS Ospedale San Raffaele

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2029-12-31
Completion
2032-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303218 on ClinicalTrials.gov